HYOSCINE HYDROCHLORIDE
CAS No. 55-16-3
HYOSCINE HYDROCHLORIDE( —— )
Catalog No. M20466 CAS No. 55-16-3
HYOSCINE HYDROCHLORIDE versus placebo in preventing motion sickness has been shown to be effective.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 10MG | 49 | In Stock |
|
| 25MG | 75 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameHYOSCINE HYDROCHLORIDE
-
NoteResearch use only, not for human use.
-
Brief DescriptionHYOSCINE HYDROCHLORIDE versus placebo in preventing motion sickness has been shown to be effective.
-
DescriptionHYOSCINE HYDROCHLORIDE versus placebo in preventing motion sickness has been shown to be effective.
-
In VitroScopolamine blocks nicotinic acetylcholine receptors (IC50=928 μM) and increases the expression of α7 nACh receptors. Scopolamine displays concentration-dependent competition with 0.6 nM [3H]Granisetron, yielding an average pKi of 5.17±0.24 (Ki=6.76 μM). Concentration-dependent competition of fluorescently labeled form of granisetron (G-FL) with Scopolamine gives an average pKi of 5.31±0.09 (Ki=4.90 μM).Scopolamine blocks muscarinic receptors and induces a cognitive deficit.Scopolamine (0.1-3 mM; for 24 hours) induces cytotoxicity, ROS generation and apoptosis of SH-SY5Y cells.Cell Viability Assay Cell Line:Human neuroblastoma SH-SY5Y cell line Concentration:0.1-3 mM (usually 2 mM) Incubation Time:24 hours Result:Exposure to 1-3 mM for 24 hours significantly decreased human neuroblastoma SH-SY5Y cell viability in a dose-dependent manner. In all subsequent experiments, 2 M resulted in 50.6±2.2% loss in cell viability.
-
In VivoScopolamine induces memory impairment associated with attenuation of cholinergic neurotransmission, as well as an increases of processes connected with oxidative stress in the brain. Animal Model:Naive male Swiss mice weighing 20-25 Dosage:1mg/kg Administration: Administered intraperitoneally (i.p.); to measure the memory acquisition processes, Scopolamine was administered 20 min before the pretest; to measure the memory consolidation processes, Scopolamine was administered immediately after the pretest Result:In scopolamine-treated group, there was a significant decrease in the index of latency (IL) value as compared with the saline-treated mice, indicating that scopolamine at the used dose impaired acquisition of memory and learning.
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number55-16-3
-
Formula Weight339.8
-
Molecular FormulaC17H22ClNO4?
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCl.[H][C@@]12O[C@]1([H])[C@H]1C[C@H](C[C@@H]2N1C)OC(=O)[C@H](CO)c1ccccc1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Spinks A Wasiak J . Scopolamine (hyoscine) for preventing and treating motion sickness[J]. Cochrane database of systematic reviews (Online) 2011(6):CD002851.
molnova catalog
related products
-
Tricetin 7-O -glucos...
Tricetin 7-O -glucoside
-
Thalidomide-O-C4-NH2...
Thalidomide-linker 9 is a synthesized?E3 ligase ligand-linker conjugate?that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.
-
NTRC 0066-0
NTRC 0066-0 is an orally available, selective and potent inhibitor of threonine tyrosine kinase (TTK) that inhibits phosphorylation of TTK substrates and induces chromosome missegregation in cell lines and mice for cancer research.
Cart
sales@molnova.com